Mirum Pharmaceuticals Stock Performance
| MIRM Stock | USD 105.10 2.27 2.21% |
On a scale of 0 to 100, Mirum Pharmaceuticals holds a performance score of 20. The company secures a Beta (Market Risk) of 0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mirum Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Mirum Pharmaceuticals is expected to be smaller as well. Please check Mirum Pharmaceuticals' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Mirum Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mirum Pharmaceuticals are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Mirum Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.21 | Five Day Return 2.95 | Year To Date Return 34.62 | Ten Year Return 695.61 | All Time Return 695.61 |
1 | Disposition of 50000 shares by Grey Michael G of Mirum Pharmaceuticals at 70.0 subject to Rule 16b-3 | 11/21/2025 |
2 | Acquisition by Grey Michael G of 6268 shares of Mirum Pharmaceuticals at 44.0 subject to Rule 16b-3 | 12/05/2025 |
3 | Mirum Pharmaceuticals Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback | 12/11/2025 |
4 | Mirum Pharmaceuticals to raise 68.5M in private placement with TCGX - MSN | 12/29/2025 |
5 | Disposition of 21070 shares by Christopher Peetz of Mirum Pharmaceuticals subject to Rule 16b-3 | 12/31/2025 |
6 | Mirum Pharmaceuticals Valuation Check After Strong Share Price Momentum And Rare Disease Pipeline Updates | 01/27/2026 |
7 | Acquisition by Christopher Peetz of 43500 shares of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/28/2026 |
8 | Mirum Pharmaceuticals Is Up 6.5 percent After Bluejay Acquisition and 2026 Sales Outlook Update - Whats Changed | 02/02/2026 |
9 | Howe Jolanda, SVP at Mirum Pharmaceuticals, sells 99997 in Mirm stock - Investing.com | 02/03/2026 |
10 | Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahep... | 02/05/2026 |
11 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/11/2026 |
12 | Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 | 02/18/2026 |
| Begin Period Cash Flow | 286.3 M | |
| Total Cashflows From Investing Activities | -90.1 M |
Mirum Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,097 in Mirum Pharmaceuticals on November 21, 2025 and sell it today you would earn a total of 3,413 from holding Mirum Pharmaceuticals or generate 48.09% return on investment over 90 days. Mirum Pharmaceuticals is currently generating 0.7027% in daily expected returns and assumes 2.692% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Mirum, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mirum Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Mirum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 105.10 | 90 days | 105.10 | about 5.26 |
Based on a normal probability distribution, the odds of Mirum Pharmaceuticals to move above the current price in 90 days from now is about 5.26 (This Mirum Pharmaceuticals probability density function shows the probability of Mirum Stock to fall within a particular range of prices over 90 days) .
Mirum Pharmaceuticals Price Density |
| Price |
Predictive Modules for Mirum Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mirum Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Mirum Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mirum Pharmaceuticals is not an exception. The market had few large corrections towards the Mirum Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mirum Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mirum Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.61 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 13.60 | |
Ir | Information ratio | 0.22 |
Mirum Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mirum Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mirum Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 336.89 M. Net Loss for the year was (87.94 M) with profit before overhead, payroll, taxes, and interest of 377.04 M. | |
| Mirum Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Discipline and Rules-Based Execution in CNTA Response - Stock Traders Daily |
Mirum Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mirum Stock often depends not only on the future outlook of the current and potential Mirum Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mirum Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.5 M | |
| Cash And Short Term Investments | 280.3 M |
Mirum Pharmaceuticals Fundamentals Growth
Mirum Stock prices reflect investors' perceptions of the future prospects and financial health of Mirum Pharmaceuticals, and Mirum Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mirum Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 6.12 B | ||||
| Shares Outstanding | 59.88 M | ||||
| Price To Earning | (5.20) X | ||||
| Price To Book | 21.15 X | ||||
| Price To Sales | 13.05 X | ||||
| Revenue | 336.89 M | ||||
| Gross Profit | 377.04 M | ||||
| EBITDA | (48.97 M) | ||||
| Net Income | (87.94 M) | ||||
| Cash And Equivalents | 124.95 M | ||||
| Cash Per Share | 3.82 X | ||||
| Total Debt | 317.76 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.26 X | ||||
| Book Value Per Share | 5.69 X | ||||
| Cash Flow From Operations | 10.32 M | ||||
| Earnings Per Share | (0.84) X | ||||
| Market Capitalization | 6.16 B | ||||
| Total Asset | 670.75 M | ||||
| Retained Earnings | (644.18 M) | ||||
| Working Capital | 266.24 M | ||||
| Current Asset | 106.8 M | ||||
| Current Liabilities | 11.7 M | ||||
About Mirum Pharmaceuticals Performance
By examining Mirum Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Mirum Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mirum Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 115.18 | 200.10 | |
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.45) | (0.47) |
Things to note about Mirum Pharmaceuticals performance evaluation
Checking the ongoing alerts about Mirum Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mirum Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 336.89 M. Net Loss for the year was (87.94 M) with profit before overhead, payroll, taxes, and interest of 377.04 M. | |
| Mirum Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Discipline and Rules-Based Execution in CNTA Response - Stock Traders Daily |
- Analyzing Mirum Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mirum Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Mirum Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mirum Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mirum Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mirum Pharmaceuticals' stock. These opinions can provide insight into Mirum Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.84) | Revenue Per Share | Quarterly Revenue Growth 0.472 | Return On Assets | Return On Equity |
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value - what Mirum Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.